Trupanion Inc
$ 24.92
-3.82%
06 May - close price
- Market Cap 1,130,206,000 USD
- Current Price $ 24.92
- High / Low $ 26.27 / 24.91
- Stock P/E 43.92
- Book Value 8.85
- EPS 0.59
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.07 %
- 52 Week High 57.88
- 52 Week Low 23.80
About
Trupanion, Inc. offers monthly subscription medical insurance for dogs and cats in the United States, Canada, Puerto Rico and Australia. The company is headquartered in Seattle, Washington.
Analyst Target Price
$39.75
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-12 | 2025-10-28 | 2025-08-07 | 2025-04-30 | 2025-02-13 | 2024-10-30 | 2024-08-08 | 2024-05-02 | 2024-02-15 | 2023-11-02 | 2023-08-03 |
| Reported EPS | 0.7759 | 0.13 | 0.7669 | 0.22 | 0.19 | 0.0391 | 0.03 | -0.14 | -0.16 | -0.05 | -0.1 | -0.33 |
| Estimated EPS | 0.0615 | 0.1617 | 0.0196 | -0.04 | -0.2 | 0.84 | -0.06 | -0.18 | -0.2 | -0.18 | -0.31 | -0.41 |
| Surprise | 0.7144 | -0.0317 | 0.7473 | 0.26 | 0.39 | -0.8009 | 0.09 | 0.04 | 0.04 | 0.13 | 0.21 | 0.08 |
| Surprise Percentage | 1161.626% | -19.6042% | 3812.7551% | 650% | 195% | -95.3452% | 150% | 22.2222% | 20% | 72.2222% | 67.7419% | 19.5122% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TRUP
2026-05-06 17:09:07
The article discusses the "Life Insurance In Force" metric for Trupanion, Inc. (LSE:0LH0). It appears to be a financial data point provided by TradingView for the London Stock Exchange listing of Trupanion, Inc. The page structure suggests that more detailed financial data would typically be displayed here.
2026-05-05 15:39:20
Trupanion (TRUP) reported its fourth consecutive profitable quarter and record adjusted operating income, with a swing to net income of US$4.88 million in Q1 2026. Despite these strong results and growing subscription margins, the stock is down 10.7%. The article suggests that while current profitability is strong, underlying risks include potential overreliance on higher average revenue per pet and the impact of rising prices on actual pet growth.
2026-05-04 19:38:50
Trupanion (TRUP) reported a profitable Q1 2026, swinging to a net income of US$4.88 million with strong subscription margins and record adjusted operating income. Despite these positive financial results, the stock is down 10.7%. The article discusses how these results impact Trupanion's investment narrative, highlighting its subscription model's potential for durable growth against risks like rising prices masking weak pet growth and competition.
2026-05-04 11:10:18
Margi Tooth, CEO of Trupanion, the largest pet insurer in the U.S., shares her journey from dreaming of being a vet to leading a company that insures over a million pets and generates over $1 billion in annual revenue. She emphasizes the importance of collaboration, building a trusted team, continuous learning, and trusting one's instincts in leadership. Tooth also discusses overcoming workplace barriers and negative self-talk, crediting her mentors and family for their unwavering support.
2026-05-03 17:35:53
This article summarizes a bullish thesis on Trupanion, Inc. (TRUP), highlighting its subscription-driven pet insurance model, disciplined capital deployment, and potential for long-term intrinsic value growth despite recent margin compression. The company's competitive moat is attributed to its point-of-care distribution and strong retention, with management guiding for 13-15% subscription growth and about 15% margins by FY2026. The article suggests TRUP is an underappreciated compounder with improving economics.
2026-05-03 05:39:53
Trupanion (TRUP) has seen a recent 1.4% gain, but longer-term returns have been weaker. Despite a fair value estimate of $46.25 suggesting it's undervalued based on future earnings and technological efficiencies, the company trades at a high P/E ratio of 41x compared to the industry average. Key risks include reliance on price increases and rising competition, urging investors to examine the underlying data beyond just the fair value estimate.
